{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:41:46Z","timestamp":1793227306113,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:46:12Z","timestamp":1732866372000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice"],"prefix":"10.1016","volume":"47","author":[{"given":"M.","family":"Marassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.11.005_bib0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0002","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0003","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0006","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0007","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0009","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England J Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0010","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0011","unstructured":"Novo Nordisk. Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis [Internet]. [access date: 2024 Mar 27]; Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=167028."},{"key":"10.1016\/j.clinthera.2024.11.005_bib0012","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0013","unstructured":"FDA approves first oral GLP-1 treatment for type 2 diabetes | FDA [Internet]. [access date: 2024 Aug 31];Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-glp-1-treatment-type-2-diabetes."},{"key":"10.1016\/j.clinthera.2024.11.005_bib0014","unstructured":"Rybelsus | European Medicines Agency (EMA) [Internet]. [access date: 2024 Aug 31]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybelsus."},{"key":"10.1016\/j.clinthera.2024.11.005_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0016","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0017","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0018","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0020","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0021","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0022","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0023","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.37765\/ajmc.2020.88554","article-title":"Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care","volume":"26","author":"Rodbard","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0024","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","author":"Husain","year":"2019","journal-title":"New England J Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0025","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0027","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/dom.14054","article-title":"Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0028","unstructured":"Rybelsus Summary of Product Characteristics. [Internet]. [access date: 2024 Mar 24]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf."},{"key":"10.1016\/j.clinthera.2024.11.005_bib0029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13903","article-title":"Real-world evidence to support regulatory submissions: a landscape review and assessment of use cases","volume":"17","author":"Alipour-Haris","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0031","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/dom.15493","article-title":"Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: a multicentre, prospective real-world study (PIONEER REAL Canada)","volume":"26","author":"Jain","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0032","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/dom.14453","article-title":"Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study","volume":"23","author":"Aroda","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0033","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40618-024-02309-2","article-title":"Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study","volume":"47","author":"Bonora","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0034","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/dom.15431","article-title":"Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: a nationwide multicentre retrospective observational study (ENDO2 S-RWD)","volume":"26","author":"Moreno-P\u00e9rez","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0035","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.3390\/jcm12186052","article-title":"Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes","volume":"12","author":"Candido","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0036","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1007\/s12325-023-02677-w","article-title":"Real-world hemoglobin A1c changes, prescribing provider types, and medication dose among patients with type 2 diabetes mellitus initiating treatment with oral semaglutide","volume":"40","author":"Frazer","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0037","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s13300-024-01590-x","article-title":"Real-world clinical experience of oral semaglutide in a secondary diabetes clinic in the UK: A retrospective observational study","volume":"15","author":"Williams","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0038","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/dom.15516","article-title":"Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7\u2009mg or 14\u2009mg of oral semaglutide","volume":"26","author":"Swift","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0039","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13300-023-01525-y","article-title":"Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","volume":"15","author":"Kick","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0040","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dc24-S008","article-title":"Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0041","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1507\/endocrj.EJ23-0648","article-title":"Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)","volume":"71","author":"Furusawa","year":"2024","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0042","first-page":"176","article-title":"Retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in japanese clinical settings","volume":"10","author":"Yamada","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0043","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s13300-023-01490-6","article-title":"Clinical features, cardiovascular risk profile, and therapeutic trajectories of patients with type 2 diabetes candidate for oral semaglutide therapy in the italian specialist care","volume":"14","author":"Morieri","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0044","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0045","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0046","doi-asserted-by":"crossref","first-page":"303","DOI":"10.14740\/cr1441","article-title":"A significant effect of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes","volume":"13","author":"Yanai","year":"2022","journal-title":"Cardiol Res"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0047","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00325481.2020.1798638","article-title":"Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo","volume":"132","author":"Lavernia","year":"2020","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0048","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s13300-024-01625-3","article-title":"Suitability and usefulness of a flexible dosing timing of oral semaglutide to maximize benefit in clinical practice: an expert panel","volume":"15","author":"Candido","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231211402","article-title":"Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience","volume":"51","author":"Jani\u0107","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0051","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0052","article-title":"Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes","volume":"2","author":"Overgaard","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107031","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"199","author":"Ding","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0054","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0055","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13300-024-01551-4","article-title":"Real-world use of oral and subcutaneous semaglutide in routine clinical practice in the UK: a single-centre, retrospective observational study","volume":"15","author":"Roy Chowdhury","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0056","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/dom.15554","article-title":"Oral or injectable semaglutide for the management of type 2 diabetes in routine care: a multicentre observational study comparing matched cohorts","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0057","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s40618-024-02369-4","article-title":"Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?","volume":"47","author":"Formichi","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0059","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2169\/internalmedicine.1441-22","article-title":"Daily glucose profiles after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus","volume":"63","author":"Takahara","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0060","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0061","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0062","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.clinthera.2020.06.004","article-title":"Assessment of the regulatory dialogue between pharmaceutical companies and the European Medicines Agency on the choice of noninferiority margins","volume":"42","author":"Althunian","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0063","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s12325-019-01125-y","article-title":"Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States","volume":"36","author":"Hunt","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0064","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/13696998.2020.1722678","article-title":"Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis","volume":"23","author":"Hansen","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00592-019-01445-z","article-title":"Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy","volume":"57","author":"Fadini","year":"2020","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0066","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s13300-024-01614-6","article-title":"PIONEER real sweden: a multicentre, prospective, real-world observational study of oral semaglutide use in adults with type 2 diabetes in Swedish clinical practice","volume":"15","author":"Catrina","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0067","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s13300-024-01588-5","article-title":"Real-world use of oral semaglutide in adults with type 2 diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study","volume":"15","author":"van Houtum","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2024.11.005_bib0068","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/jdi.14291","article-title":"PIONEER REAL Japan: primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type\u20092 diabetes in japanese clinical practice","volume":"15","author":"Yabe","year":"2024","journal-title":"J Diabetes Investig"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824003308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:57:32Z","timestamp":1736348252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824003308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0149291824003308"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}